granzyme A Antibody (CB9): sc-56115

Granzyme A Antibody (CB9) is a mouse monoclonal IgG1 antibody that detects granzyme A in human samples through applications such as immunoprecipitation (IP), immunofluorescence (IF), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Granzyme A is a serine protease that plays a crucial role in the apoptotic signaling pathways of cytotoxic T lymphocytes (CTL) and natural killer (NK) cells, functioning as a key mediator of programmed cell death. Anti-granzyme A antibody (CB9) enables detection of this protein, which is synthesized as an inactive proenzyme and stored in cytolytic granules, awaiting release during the degranulation process of activated immune cells. Upon activation, granzyme A induces apoptosis through a unique mechanism involving single-strand DNA breaks, membrane perturbation, and nuclear condensation, occurring independently of the caspase activation pathway. This alternative apoptotic pathway is particularly important in immune responses, as granzyme A allows for the elimination of infected or malignant cells without caspase-mediated signaling, providing a rapid and effective means of controlling cellular threats. Granzyme A monoclonal antibody (CB9) is essential for researchers studying immune responses, apoptosis, and the intricate signaling mechanisms that govern cell death, making this reagent a valuable tool in both basic and applied biomedical research.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

granzyme A Antibody (CB9) References:

1. Granzyme A produces bioactive IL-1β through a nonapoptotic inflammasome-independent pathway.  |  Hildebrand, D., et al. 2014. Cell Rep. 9: 910-7. PMID: 25437548
2. SERPINB12 Is a Slow-Binding Inhibitor of Granzyme A and Hepsin.  |  Niehaus, JZ., et al. 2015. Biochemistry. 54: 6756-9. PMID: 26497600
3. Granzyme A potentiates chemokine production in IL-17-stimulated keratinocytes.  |  Cheuk, S., et al. 2017. Exp Dermatol. 26: 824-827. PMID: 28094457
4. Granzyme A Deficiency Breaks Immune Tolerance and Promotes Autoimmune Diabetes Through a Type I Interferon-Dependent Pathway.  |  Mollah, ZUA., et al. 2017. Diabetes. 66: 3041-3050. PMID: 28733313
5. Granzyme A Participates in the Pathogenesis of Infection-Associated Acute Encephalopathy.  |  Yamanaka, G., et al. 2020. J Child Neurol. 35: 208-214. PMID: 31709864
6. Granzyme A inhibition reduces inflammation and increases survival during abdominal sepsis.  |  Garzón-Tituaña, M., et al. 2021. Theranostics. 11: 3781-3795. PMID: 33664861
7. Improved Purification of Human Granzyme A/B and Granulysin Using a Mammalian Expression System.  |  Rasi, V., et al. 2022. Front Immunol. 13: 830290. PMID: 35300343
8. 4-Octyl itaconate blocks GSDMB-mediated pyroptosis and restricts inflammation by inactivating granzyme A.  |  Gong, W., et al. 2024. Cell Prolif. 57: e13711. PMID: 38982510
9. Association of CD8+TILs co-expressing granzyme A and interferon-γ with colon cancer cells in the tumor microenvironment.  |  Yang, J., et al. 2024. BMC Cancer. 24: 869. PMID: 39030523
10. Granzyme A as biomarker for diagnosis in tuberculous pleural effusion.  |  Li, F., et al. 2024. JCI Insight. 9: PMID: 39641275

The preferred granzyme A antibody is granzyme A Antibody (3G8.5): sc-33692.